2015 – 2026 · TEM · CIK 1717115
Tempus AI Leadership
Founder-CEO Eric Lefkofsky's Groupon-and-prior-ventures lineage, the February 2026 executive-team restructuring that promoted Ryan Fukushima from COO to CEO of the Data product line and named Tom Schoenherr (concurrent CEO of acquired Ambry Genetics) as CEO of Diagnostics, the six-person executive officer roster, the nine-director board (eight of whom are independent under Nasdaq listing standards), and the dual-class share structure that gives Class B holders 30 votes per share — concentrating 58.3% of total voting power in directors and officers as a group. Sourced from the April 7, 2026 DEF 14A proxy statement.
Sibling pages: Tempus AI Financials · Roster row: Tempus AI on /orgs/ · AI pure-plays: /ai/orgs/.
Founder — sole founder, CEO and Chairman since inception
Tempus AI has a single founder. Eric Lefkofsky founded the company in August 2015 (originally as Bioin, LLC), has held the Founder + CEO + Chairman titles continuously since inception, and is the rare AI pure-play CEO who is also a serial-billion-dollar-company founder — he co-founded Groupon (where he was CEO 2013–2015 and Chairman 2015–2020), Mediaocean, InnerWorkings, Echo Global Logistics, and Pathos AI before founding Tempus, plus Lightbank LLC (the venture firm where he is managing member and general partner since 2008). The Tempus AI financials page intentionally defers Lefkofsky's biographical material to this page; here it gets a dedicated profile.
Founder of Tempus AI in August 2015 (then Bioin, LLC); has held CEO and Chairman titles continuously since inception. Previously co-founded Groupon, Inc. in 2008 — held various roles including board member (through November 2023), Chairman (November 2015–June 2020), Executive Chairman (through August 2013), and CEO (August 2013–November 2015). Co-founded Lightbank LLC (private VC firm, managing member since 2008, general partner since January 2019), InnerWorkings, Mediaocean, Echo Global Logistics, and Pathos AI. Northwestern Memorial Healthcare board director since February 2024. Bachelor's degree from University of Michigan; J.D. from University of Michigan Law School.
The same Delaware corporation has carried four names. Founded as Bioin, LLC in August 2015 (Delaware); converted to a Delaware corporation in September 2015 as Bioin, Inc.; renamed Tempus Health, Inc. later in 2015; renamed Tempus Labs, Inc. in 2016; renamed Tempus AI, Inc. in December 2023. Reincorporated from Delaware to Nevada effective August 7, 2025. Through every rename, Lefkofsky's CEO and Chairman titles have not changed.
Voting structure — Class A vs. Class B (30:1 founder voting)
Tempus AI's most distinctive governance feature: a dual-class share structure in which Class B common stock carries thirty times the voting power of Class A common stock.
Class A common stock
1 vote / share
The class purchased on the public market via the June 2024 IPO. Held by public shareholders broadly.
Class B common stock
30 votes / share
Super-voting class. As of March 27, 2026, all 5,043,789 Class B shares are held by current directors and officers.
Concentration of voting power. The proxy's beneficial-ownership table reports that all current directors and executive officers as a group (13 persons) hold 22.1% of Class A common stock and 100% of Class B common stock, representing 58.3% of total voting power (combining both classes as a single voting block). Lefkofsky personally holds the bulk of the Class B position via Black Media, LLC (178,485 Class B shares) and Blue Media, LLC (4,865,304 Class B shares), both LLCs of which he is sole manager. Lefkofsky's combined Class A holdings (held directly, via Black/Blue/Gray Media LLCs, the Lefkofsky Family Foundation, the Vas.org Foundation, the Lefkofsky Family 2025 GRAT, and 346 Long LLC) plus the Class B holdings give him a majority of Tempus AI's voting power as a single individual.
Sunset / conversion provisions. The proxy describes the dual-class structure but does not surface explicit Class B sunset language at the level the matched-set Palantir-leadership page surfaces for Palantir's Class F. The certificate of incorporation (filed as an exhibit to the IPO registration statement) is the canonical source for transfer-restriction and conversion provisions; visitors who want the full text should read that exhibit directly.
Source: 2026 DEF 14A, “Security Ownership of Certain Beneficial Owners and Management” section, beneficial-ownership table footnote on Class A vs. Class B voting rights and the “13 persons” aggregate.
Current executive officers
Six executive officers as of April 7, 2026, per the 2026 DEF 14A proxy statement. The roster reflects the February 20, 2026 restructuring in which Ryan Fukushima was promoted from Chief Operating Officer to CEO, Data; Tom Schoenherr (concurrent CEO of Ambry Genetics, acquired by Tempus February 2025) was named CEO, Diagnostics; and Andrew Polovin was promoted from General Counsel to Chief Legal Officer. Click any row for the bio detail.
Eric Lefkofsky
56
Founder, Chief Executive Officer, Chairman of the Board
2015 (founding)
See the founder profile at the top of the page for the Groupon / Lightbank / serial-founder lineage.
Ryan Fukushima
40
Promoted Feb 2026 · Chief Executive Officer, Data
2015
CEO, Data since February 2026; previously Chief Operating Officer from September 2015 to February 2026 (the company's first major executive hire after Lefkofsky). Pre-Tempus: Entrepreneur-in-Residence and Vice President at Lightbank LLC (Lefkofsky's VC firm) from February 2014 to September 2015. Concurrent service as CEO of Pathos AI, Inc. from July 2021 to May 2025 (Pathos is one of Lefkofsky's other founded companies); now serves as Pathos AI advisor and board member. The 2025 base-salary footnote notes that Mr. Fukushima had previously devoted approximately half of his professional time to Pathos AI before returning to full-time status with Tempus mid-year. B.S. from California Polytechnic University; M.B.A. from the Ross School of Business at the University of Michigan.
Tom Schoenherr
52
New, Feb 2026 · Chief Executive Officer, Diagnostics
2025 (via Ambry)
CEO, Diagnostics since February 2026. Concurrent CEO of Ambry Genetics Corporation since May 2021 — continuing in the Ambry CEO role following Tempus's February 2025 acquisition of Ambry, which added the Hereditary testing line to the Diagnostics product. Previously Ambry's Chief Commercial Officer from November 2017 to May 2021. Twenty-plus years of executive leadership in molecular diagnostics, including Chief Commercial Officer at Omada Health (virtual care for chronic disease management) August 2016 to August 2017. B.S. from Michigan State University; Executive Business Development Program at the University of Notre Dame.
Andrew Polovin
52
Promoted Feb 2026 · Executive Vice President, Chief Legal Officer and Secretary
June 2020
Chief Legal Officer since February 2026; previously General Counsel from June 2020 to February 2026. Has served as Executive Vice President and Secretary since April 2024. Pre-Tempus: General Counsel and Secretary of Uptake Technologies, Inc. (industrial-machinery AI software) from August 2016 to June 2020. Earlier: partner at Bartlit Beck (a leading trial-litigation boutique), Assistant United States Attorney in the Northern District of Illinois, and clerk for the Chief Judge of the United States Court of Appeals. B.A. Colgate University; J.D. Northwestern University School of Law.
James Rogers
40
Chief Financial Officer
August 2017
CFO since April 2021. Previously Vice President of Finance from April 2020 to April 2021 and Senior Director of Finance from August 2017 to April 2020. Pre-Tempus: various finance positions at Groupon, Inc. from April 2011 to August 2017 — the Lefkofsky-Groupon lineage extends to the Tempus CFO seat. Most recently led FP&A for Groupon's North America business (February 2017–August 2017) and served as financial controller of Asia Pacific operations (January 2015–January 2017). B.B.A. from the University of Notre Dame; M.S. from Northern Illinois University.
Erik Phelps
—
Executive Vice President, Chief Administrative Officer and Assistant Secretary
—
EVP, Chief Administrative Officer and Assistant Secretary; named-executive-officer for fiscal year 2025 with a $610,000 base salary and 50% target bonus. Bio detail beyond the named-executive-officer compensation tables is not in the body of the 2026 DEF 14A.
Ages, positions, and tenure as listed in the 2026 DEF 14A. Each executive officer serves at the discretion of the Board.
Board of directors
Nine directors as of April 7, 2026, all standing for re-election to one-year terms expiring at the 2027 Annual Meeting. Eight of nine are independent under Nasdaq listing standards (only founder-CEO Lefkofsky is not). The board carries an unusual concentration of healthcare, biotech, and life-sciences leadership relative to most AI pure-plays — including a Nobel laureate (Doudna), a former FDA Commissioner (Gottlieb), a former U.S. Army Surgeon General (West), and a former Howard University president (Frederick).
Eric Lefkofsky
56
Chairman of the Board · Founder, CEO; Executive Committee · NomGov Observer
2015 (inception)
Management director (not independent). Combined Founder + CEO + Chairman role since inception. See the founder profile for the full Groupon / Lightbank lineage and the voting structure for the dual-class concentration he holds.
Peter J. Barris
74
Independent · Audit, Compensation & Executive Committees
September 2017
The earliest non-Lefkofsky director. Chairman Emeritus of New Enterprise Associates (NEA) — joined NEA in 1992, Managing General Partner 1999–2017, retired end of 2019. Sprout Social board director since February 2011. Previously served on the boards of Berkshire Grey, ZeroFox Holdings, NextNav, and Groupon (January 2008 to August 2022). Chairman Emeritus of Northwestern University. B.S. Northwestern; M.B.A. Tuck School of Business at Dartmouth.
Eric D. Belcher
57
Independent · Audit Committee
January 2019
CEO of Numerator (formerly Market Track LLC; data and technology company in market research) since June 2019. Previously CEO and President of InnerWorkings, Inc. (one of Lefkofsky's other founded companies) from January 2009 to April 2018, and InnerWorkings board chairman April 2018 to September 2018. Bachelor's from Bucknell University; M.B.A. from University of Chicago Booth School of Business.
Theodore J. Leonsis
70
Independent · NomGov & Executive Committees
January 2019
Co-founded Revolution Growth (private investment firm, General Partner since November 2011). Founder, Chairman, Majority Owner and CEO of Monumental Sports & Entertainment (NBA Washington Wizards, NHL Washington Capitals, WNBA Washington Mystics, Capital City Go-Go) since 1999. American Express Co. director since July 2010. Groupon board director since June 2009; Chairman August 2013–November 2015 and again since June 2020 — making Leonsis a multi-decade business associate of Lefkofsky's. Bachelor's from Georgetown University.
Scott Gottlieb, M.D.
53
Independent · NomGov Committee
October 2019
23rd Commissioner of the U.S. Food and Drug Administration from May 2017 to April 2019. Concurrent boards: UnitedHealth Group (since November 2025), Illumina (since February 2020), Pfizer (since June 2019). Partner on NEA's healthcare investment team since April 2019; Resident Fellow at American Enterprise Institute since April 2021. CNBC contributor and CBS News Face the Nation contributor. Mount Sinai Health System board executive committee. B.A. Wesleyan University; M.D. Mount Sinai School of Medicine.
Wayne A.I. Frederick, M.D.
54
Independent · Audit Committee
October 2020
President Emeritus of Howard University (after serving as President from July 2014). Charles R. Drew Endowed Chair of Surgery at Howard University's College of Medicine. Interim CEO of the American Cancer Society and its Cancer Action Network from November 2024 to August 2025. Concurrent boards: Workday (since July 2022), Insulet Corp (since October 2020), Humana (since February 2020). B.S./M.D. dual degree and M.B.A. from Howard University.
Jennifer A. Doudna, Ph.D.
62
Independent · NomGov Committee
April 2021
Nobel Prize in Chemistry, 2020 (CRISPR-Cas9 genome editing). Professor of Biochemistry & Molecular Biology at UC Berkeley since July 2002, where she directs the Innovative Genomics Institute (joint UC Berkeley/UC San Francisco). Founder and Scientific Advisory Board member of Caribou Biosciences and Intellia Therapeutics (both leading CRISPR genome-engineering companies) since 2010. Howard Hughes Medical Institute Investigator since 1997. Johnson & Johnson board director since April 2018. Bachelor's from Pomona College; Ph.D. from Harvard Medical School.
Nadja West, M.D.
65
Independent · Compensation Committee
April 2021
44th Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command, December 2015 to October 2019. Concurrent boards: Johnson & Johnson (since December 2020), Tenet Healthcare (since October 2019), Nucor Corporation (since September 2019). NCAA Board of Governors independent member; Trustee of National Recreation Foundation and Mount St. Mary's University. B.S. United States Military Academy at West Point; M.D. The George Washington University School of Medicine; M.S. National War College.
David R. Epstein
64
Independent · Newest, Feb 2024 · Compensation & NomGov Committees
February 2024
Newest director (joined February 2024). Chairman and CEO of Ottimo Pharma Limited since October 2024. CEO and director of Seagen Inc. from November 2022 until Seagen's acquisition by Pfizer in December 2023. From 2010 to mid-2016, CEO of Novartis Pharmaceuticals (a division of Novartis AG); previously started and led Novartis's Oncology and Molecular Diagnostic units, growing the oncology business to the second-largest in the world. Earlier: consultant and executive partner at Flagship Pioneering 2017–October 2022; Senior Advisor / Chairman / director of multiple biotech companies. B.S. pharmacy from Rutgers University College of Pharmacy; M.B.A. finance and marketing from Columbia University Graduate School of Business.
Ages, committee assignments, and director-since dates as listed in the 2026 DEF 14A. The 2026 Annual Meeting nominates all nine directors for one-year terms (Tempus AI does not have a classified board; every director stands for election every year). Independence determinations: Nasdaq listing standards for general independence; Rule 10A-3 for the Audit Committee (Belcher, Barris, Frederick); Rule 10C-1 for the Compensation Committee (Barris, Epstein, West).
February 2026 executive-team restructuring
A material restructuring of the executive team announced effective February 20, 2026 realigned officer titles around the company's two product lines (Diagnostics, Data and applications) and elevated Andrew Polovin's title to reflect a broader legal-officer scope. The proxy describes each promotion in the named-executive-officer footnotes.
Source: 2026 DEF 14A, Compensation Discussion and Analysis named-executive-officer footnotes.
Notable departures
None disclosed as of the 2026 DEF 14A. The current executive officer roster (Lefkofsky, Fukushima, Schoenherr, Polovin, Rogers, Phelps) and the nine-director board represent a stable cohort — the February 2026 restructuring documented above involved title changes and product-line realignments, not officer departures. New departures, when they happen, will be added here in the same matched-set shape as the Palantir leadership departures table.
Read these primary sources
Most of the page's content is paraphrased from the URLs below. They are the authoritative places to read what Tempus AI has said in its own SEC filings.
Tempus AI SEC filings
The 2026 DEF 14A (Tempus's first-ever proxy statement, since the company was an Emerging Growth Company through fiscal year 2025) is the canonical source for the current officer + director rosters, the Class A vs. Class B voting structure, and the February 2026 restructuring narrative. The FY2025 10-K supplements with Item 10 (Directors and Executive Officers).
# 2026 DEF 14A — first-ever proxy statement; canonical source for governance
https://www.sec.gov/Archives/edgar/data/1717115/000119312526145528/d23945ddef14a.htm
# FY2025 10-K — Item 10 (Directors and Executive Officers)
https://www.sec.gov/Archives/edgar/data/1717115/000119312526066961/tem-20251231.htm
# Tempus AI on EDGAR — full filing history
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001717115
# EDGAR submissions JSON — full filing index for Tempus AI
https://data.sec.gov/submissions/CIK0001717115.jsonTempus AI's own pages
The company's IR site is the company-side framing reference for the leadership team.
# Tempus AI corporate site
https://www.tempus.com/
# Investor Relations
https://investors.tempus.com/
# Lightbank — Lefkofsky's VC firm (managing member since 2008)
https://www.lightbank.com/
# Pathos AI — Lefkofsky-co-founded company; Fukushima was CEO July 2021–May 2025
https://www.pathosai.com/Sources: Tempus AI's own SEC filings — specifically the April 7, 2026 DEF 14A proxy statement for the current officer + director rosters, the dual-class voting structure, and the February 2026 restructuring narrative; the FY2025 10-K filed February 24, 2026 for Item 10 (Directors and Executive Officers). Last updated April 2026.
Mungomash LLC · More org pages · Tempus AI Financials · Tempus AI on /orgs/ · /ai/orgs/